Volume 24, Number 4—April 2018
Research
Influenza A(H7N9) Virus Antibody Responses in Survivors 1 Year after Infection, China, 2017
Table 2
Underlying disease, complications, and treatment of influenza A(H7N9) virus survivors, China, 2017*
Patient no. | Underlying disease | Complications | Oxygen therapy | Mechanical ventilation | Days to antiviral treatment† | Oseltamivir | Glucocorticoid |
---|---|---|---|---|---|---|---|
1 | HTN, DM | ARDS, RF | Yes | No | 6 | Yes | Yes |
2 | No | ARDS, RF | Yes | No | 13 | Yes | Yes |
3 | No | ARDS, RF | Yes | No | 8 | Yes | Yes |
4 | COPD, HTN | No | Yes | No | 6 | Yes | Yes |
5 | HTN | ARDS, RF | Yes | No | 7 | Yes | Yes |
6 | HTN, DM | ARDS, HI | Yes | No | 14 | Yes | No |
7 | No | ARDS | Yes | No | 9 | Yes | Yes |
8 | No | No | Yes | No | 7 | Yes | Yes |
9 | No | No | Yes | No | 9 | Yes | Yes |
10 | No | ARDS, RF, HI, RI | Yes | Yes | 11 | Yes | Yes |
11 | No | HI | Yes | No | 7 | Yes | Yes |
12 | No | No | Yes | No | 8 | Yes | No |
13 | No | No | Yes | No | 8 | Yes | Yes |
14 | No | No | Yes | No | 6 | Yes | Yes |
15 | No | HI | Yes | No | 7 | Yes | Yes |
16 | No | RF | Yes | No | 13 | Yes | No |
17 | No | ARDS | Yes | No | 9 | Yes | Yes |
18 | No | No | Yes | No | 13 | Yes | Yes |
19 | No | RF, HI | Yes | No | 5 | Yes | Yes |
20 | HTN | ARDS, RF, HI | Yes | Yes | 11 | Yes | Yes |
21 | HTN, DM, HL | ARDS, RF, HI | Yes | Yes | 5 | Yes | Yes |
22 | HTN | ARDS, RF, HI | Yes | No | 7 | Yes | Yes |
23 | HTN | No | Yes | No | 6 | Yes | NA |
24 | NA | NA | Yes | NA | 1 | Yes | NA |
25 | CHB | HI | Yes | No | 9 | Yes | Yes |
*ARDS, acute respiratory distress syndrome; CB, chronic bronchitis; CHB, chronic hepatitis B infection; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; HI, hepatic insufficiency; HL, hyperlipidemia; HTN, hypertension; NA, not available; RF, respiratory failure; RI, renal insufficiency.
†After admission.
1These authors contributed equally to this article.